Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.
暂无分享,去创建一个
L. Schwartz | Binsheng Zhao | C. Sima | M. Kris | Gregory Riely | M. Ginsberg | G. Oxnard | L. James | R. Lefkowitz | P. Guo
[1] P. LoRusso,et al. Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction? , 2010, Clinical Cancer Research.
[2] M. Buyse,et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Binsheng Zhao,et al. Pulmonary metastases: effect of CT section thickness on measurement--initial experience. , 2005, Radiology.
[4] K. Hopper,et al. Analysis of interobserver and intraobserver variability in CT tumor measurements. , 1996, AJR. American journal of roentgenology.
[5] L. Washington,et al. Inherent variability of CT lung nodule measurements in vivo using semiautomated volumetric measurements. , 2006, AJR. American journal of roentgenology.
[6] William Pao,et al. Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] Wendy J. Post,et al. Volumetric measurement of pulmonary nodules at low-dose chest CT: effect of reconstruction setting on measurement variability , 2009, European Radiology.
[8] Binsheng Zhao,et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. , 2009, Radiology.
[9] L. Schwartz,et al. Evaluation of tumor measurements in oncology: use of film-based and electronic techniques. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Heber MacMahon,et al. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. , 2004, Medical physics.
[11] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[12] L. Broemeling,et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Richard Pazdur,et al. Accelerated approval and oncology drug development timelines. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[15] Michael L Maitland,et al. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. , 2007, Journal of the National Cancer Institute.
[16] J. Blay,et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] B. Escudier,et al. Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Manish R. Sharma,et al. A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies. , 2010 .
[19] W. Heindel,et al. Volumetric measurements of pulmonary nodules at multi-row detector CT: in vivo reproducibility , 2003, European Radiology.
[20] William Pao,et al. A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development , 2010, Clinical Cancer Research.
[21] Michael L Maitland,et al. Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis , 2010, Clinical Cancer Research.
[22] Ivan Pedrosa,et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. , 2011, European Urology.